Title: The Yellow Card Scheme: Reporting Adverse Drug Reactions
1The Yellow Card Scheme Reporting Adverse Drug
Reactions
2Objectives
- What is an Adverse Drug Reaction (ADR)?
- Classification of ADRs
- How common are ADRs?
- Identifying an ADR
- How to avoid ADRs
- The Yellow Card Scheme
- What to report
- Information to include on a Yellow Card
3What is an adverse drug reaction?
- An adverse drug reaction (ADR) is an unwanted
or harmful reaction experienced following the
administration of a drug or combination of drugs
under normal conditions of use and is suspected
to be related to the drug.
4Adverse drug reaction or adverse event
- Terms often used interchangeably not always
correct. - Adverse drug reaction is an unwanted or harmful
reaction experienced following the administration
of a drug e.g. patient experiencing anaphylaxis
shortly after taking a drug. - Adverse event is any undesirable event
experienced by a patient while taking a drug,
regardless of whether the drug is suspected to be
related to the event e.g. patient having a road
traffic accident while on a specific medication.
5Classification of ADRs
- Common ADRs
- Type A (Augmented)
- Predictable, dose related
- Constipation with opioids
- Usually not severe
- Peptic ulceration following NSAID use
6Classification of ADRs
- Uncommon but often well recognised ADRs
- Type B (Bizarre)
- Unpredictable, not dose related
- May be very severe / fatal
- Achilles tendonitis caused by quinolone
antibiotics - Stevens-Johnson syndrome following lamotrigine
therapy - With new drugs ADRs not well recognised
7Classification of ADRs
- Type C (Chronic treatment effects)
- osteoporosis with steroids
- Type D (Delayed effects)
- drug induced cancers
- Reports of skin cancers, lymphomas and other
cancers following topical pimecrolimus and
tacrolimus 1 - Type E (End of treatment effects)
- withdrawal syndromes
- Headache, anxiety, dizziness sleep disturbances,
gastro-intestinal disturbances after stopping
paroxetine.
8Classification of ADRs
- Type F (Failure of therapy)
- unexpected failure of therapy due to drug
interaction - St Johns Wort reducing efficacy of combined
hormonal contraceptives - Type G (Genetic or genomic)
- Irreversible genetic damage
- Carcinogens
- Genotoxins
- Teratogens
9Important factors in ADRs DoTS
- 3 factors Dose, Time, Susceptibility
- Dose (response) The ADR can occur
- at doses below therapeutic doses
- anaphylaxis with penicillin
- in the therapeutic dose range
- nausea with morphine
- at high doses
- liver failure with paracetamol
-
10Important factors in ADRs
- Time (course) can be characteristic
- with the first dose
- anaphylaxis with penicillin
- early, or after a time, or with long-term
treatment - first few days nitrate induced headache
- 10 days 10 weeks toxic epidermal necrolysis
- several weeks drug-induced Cushings syndrome
- on stopping treatment (withdrawal)
- paroxetine withdrawal syndrome
- delayed
- clear cell cancer with stilbestrol
-
11Important factors in ADRs
- Susceptibility of patients can be defined
- Genetics haemolysis with chloroquine in G6PD
deficiency - Age parkinsonism with prochlorperazine in the
elderly - Sex ACE-inhibitor induced cough in women
- Physiological state phenytoin in pregnancy
- Exogenous drugs or foods warfarin, cranberry
juice, and increased INR - Disease gentamicin deafness in renal failure
12Examples of ADRs
- Common and well established ADRs
- Constipation with opioids
- Abdominal pain and diarrhoea with erythromycin
therapy. - Nausea when starting fluoxetine
- Gastrointestinal symptoms with NSAIDs
- Uncommon but well recognised ADRs
- Achilles tendonitis caused by quinolone
antibiotics - Visual field defects with vigabatrin
- Uncommon emerging ADRs
- Depression with rimonabant
- AF with bisphosphonates
- Hepatoxicity with lumiracoxib
13Why are ADRs important?
- Major clinical problem increase morbidity and
mortality. - ADRs are related to 6.5 hospital admissions in
adults, and 2.1 in children 2 - 6.7 hospitalised patients sufferserious ADRs
1 - 0.15 of hospital patients suffer fatal ADRs (
5700 deaths per year) 1,2 - ADRS are 4th leading cause of death in the USA 1
- Increase hospital stay. ADRs result in the use of
seven 800 bed UK hospitals per year.2 - Financial burden on NHS 466m 2
- Up to 40 patients in the community experience
ADRs 3
1 Lazarou J, Pomeranz BH, Corey PN. Incidence of
ADRs in hospitalised patients. JAMA .1998 279
1200-1205. 2 Pirmohamed M, James S, Meakin S et
al. Adverse drug reactions as cause of admission
to hospital prospective analysis of 18 820
patients. BMJ. 2004 329(7456)15-9. 3 Martyrs
C. Adverse reactions to drugs in general
practice. BMJ 1979 2 1194-1197
14ADRs can also
- Adversely affect patient compliance
- Reduce available choice of drug treatment
- Reduce potential efficacy of drug treatment
- Reduce quality of life
- Cause diagnostic confusion
- Reduce a patients confidence in their healthcare
professional(s)
15Who might get an ADR?
- Anyone who takes a medicine!
- Differential diagnosis should include the
- possibility of an ADR if the patient is taking
any - form of medication
16Who is most at risk from ADRs?
- The elderly
- Children
- Co-existing diseases
- Females
- Atopic individuals
- Polypharmacy
- 50 of patients on 5 drugs or more
17ADRs are an increasing public health problem
- Factors
- Increase in elderly population (4 x as likely to
have ADR)1 - Increase in polypharmacy
- Increase in availability of OTC medicines
- Increase in use of herbal/traditional medicines
- Increase in medicines available via the internet
-
1 Pharm World Science 200224(2)46-54)
18Are ADRs avoidable?
- 70 ADRs are potentially avoidable 1
- More rational Prescribing
- Avoid unnecessary drug use
- Dose optimisation identify drugs known to
produce dose-related side effects - Avoid / reduce drug interactions
- Consider prophylactic therapy where appropriate
- Avoid new / black triangle drugs
- Avoid prescribing contra-indicated drugs
- Drug use in an inappropriate clinical indication
- Check drug history before prescribing
- Consider risk factors for ADRs
- Polypharmacy
- Age extremes
- Reduced hepatic and renal function
- Patient counselling re ADRs 2
- Better monitoring of treatment 3
- Better communication 4
1 Howard et al BJCP 2007 Feb63(2)136-47 2 BMJ
2006333522 3 BMJ 20033271179-1181 4
Archives of Internal medicine 2006145(4)284-293
19What should raise your suspicion?
- Timing with drug treatment.
- Abnormal clinical measurements while on drug
therapy e.g. B.P, temp, pulse, blood glucose and
weight - Abnormal laboratory results while on drug
therapy. Could be biochemical or haematological - New therapy started which could be used to treat
ADR - Patient risk factors
- Listen to patients own concerns
20Assessing causality
- Nature of the reaction
- Timing
- Relationship to dose
- Other possible causes for the symptoms
- Improvement when drug(s) stopped
- Has reaction been reported before
- Dechallenge/Rechallenge
21How common are ADRs?
- Drugs most commonly implicated include NSAID,
aspirin, diuretics and warfarin1 - Aspirin was most frequent cause for admission 2
- 18 ADR related admissions
- 162 (74) patients on aspirin 75mg OD
- 157 (72) gastro-intestinal bleeding
- In the UK Non Steroidal Anti-Inflammatory Drug
(NSAID) use alone accounts for3 - 65,000 emergency admissions/year
- 12,000 ulcer bleeding episodes/year
- 2,000 deaths/year
-
1 Howard RL et al. Which drugs cause preventable
admissions to hospital? A systematic review. Br J
Clin Pharmacol 2007 63(2)136-147 2 Pirmohamed
M et al. Adverse drug reactions as cause of
admission to hospital prospective analysis of
18 820 patients. BMJ. 2004 329(7456)15-9. 3.
Blower et al. Emergency admissions for upper
gastrointestinal disease and their relation to
NSAID use. Aliment Pharmacol Ther 1997 11
283-291
22The Yellow Card Scheme
- Introduced in 1964 after thalidomide tragedy
- Spontaneous reports of suspected adverse drug
reactions. - Acts as an early warning system to identify ADRs
and risk factors - Over 600,000 confidential reports have been
received in UK - Doctors, dentists, pharmacists, coroners, nurses,
midwifes, health visitors - Non-medical prescribers
- and now patients
- MHRA can detect duplicate reports
23- Patients can report suspected side effects
- online at www.yellowcard.gov.uk
- using the form inside this leaflet found in
pharmacies - by calling the Yellow Card hotline on 0808 100
3352
24Why report ADRs?
- Important role in patient safety
- Allows continual safety monitoring of drugs
- old new
- New drugs - lack of experience on adverse effects
- Exposure in about 1500 people only
- Short duration
- Unlikely to detect ADRs
- Less frequent than 1/1500
- With long latency
- Lack of experience in special patient groups
- Elderly, children, pregnancy, multiple disease,
polypharmacy - To detect rare adverse effects
25Strengths of Yellow Card Scheme
- Acts as early warning system for identification
of previously unrecognised reactions - Provides information about factors which
predispose patients to ADRs - Allows comparisons of ADR profiles between
products within same therapeutic class - Continual safety monitoring of a product
throughout its life span as a therapeutic agent
26Weaknesses of Yellow Card Scheme
- Cannot provide estimates of risk as
- true number of cases is underestimated
- total number of patients exposed is unknown
- Relies on ADR being recognised
- Not all ADRs are reported
- Only 10 serious reactions reported
- May be stimulated by promotion and publicity
- Reporting high for newly marketed drugs and falls
off over time - Reports do not imply causality
27Why are reporting rates low?
- Too busy
- Not sure what to report
- Uncertain of the threshold for a serious reaction
- Not easy to find a Yellow Card
- Not my responsibility
- It takes too long to complete a card
- Reporting generates too much extra work
- Duplication
- Belief that serious ADRs will be identified in
clinical trials - Confidentiality
28Completing a Yellow Card
29On-line
- Simple
- Fast
- Drop-down menus
- Allows reporter to register on the site
- The Yellow Card can be saved at any time
www.yellowcard.gov.uk
30(No Transcript)
31Who can report?
- Doctors, dentists, coroners
- Hospital pharmacists - 1997
- Community pharmacists - 1999
- Nurses, midwives and health visitors - 2002
- Patients 2008 (pilot scheme from October 2005)
- Pharmaceutical companies have a legal obligation
to report - Over 600,000 reports received to date on
voluntary basis - MHRA can detect duplicate reports
32What to report
- Report all suspected adverse drug reactions for
- new drugs (marked ?) - even if mild
- established drugs that are serious - even if well
recognised - Serious reactions include those which are
fatal, life-threatening, disabling or
incapacitating, result in or prolong
hospitalisation, congenital abnormalities or
medically significant - Reactions in children
- Drug interactions
- Herbal medicines
- Causality does not need to be established
33Black triangle drugs?
- ?indicates that the CHM/MHRA are intensively
monitoring that product - ?will be assigned to a product because-
- the drug is new to the UK market
- the drug is being administered to the patient
either by a new route of administration or a new
formulation which is considered may have an
impact on the already established risk/benefit
profile of that drug - The drug is being administered for a new
indication
34Areas of special interest
- Children
- Elderly
- Delayed drug effects (e.g. cancers)
- Congenital anomalies
- Herbal remedies
- OTC medicines
- HIV medicines
35If you suspect an ADR
- Do not assume someone else will report it
- Only 2-4 of all ADRs are reported
- Only 10 of serious suspected ADRs are reported
- Do you have to be completely certain that what
you have seen is an ADR? - No
36Information to include on a Yellow Card
- 4 critical pieces of information that must be
included on the report - - Suspected drug(s)
- Suspect reaction(s)
- Patient details
- Reporter details
37Suspected Drug(s)
- Name of medicine
- including brand and batch number if known
- Route of administration
- Daily dose
- Date medicine started
- and stopped if applicable
- Reason why the medication was given
- Multiple drugs can be listed if more than one
drug is suspected of causing the reaction
38Suspect reaction(s)
- Describe the reaction
- Include a diagnosis if relevant
- Include when the reaction occurred
- whether the reaction was considered to be serious
and complete tick box for reasons why - Document if any treatment was given for the
reaction - Eventual outcome tick relevant box
39Patient Details
- Sex of the patient
- Age at time of reaction
- Weight if known
- Do not need to know name or DOB as this could
identify patient and break patient
confidentiality - Patients initials and local identification number
(hospital or practice number) which will identify
patient to you in the event of future
correspondence
40Reporter details
- Must be completed in all cases
- Name and full address
- Need to acknowledge receipt of report and follow
up further information if necessary. - Profession
41Additional useful information
- Other medication in the last three months
including herbal and over the counter meds. - Use additional sheets if necessary.
- If no other meds are being taken or if no more
information is available say so - Include details of any
- rechallenges
- relevant medical history
- test results
- known allergies
- suspected drug interactions
42What happens to a Yellow card once received?
Provision of information
Acknowledgment and/or follow-up for more info
Commit to database
Report details entered to Sentinel database
Assessment
Yellow Cards - Adverse Drug Reaction reports
Risk-benefit evaluation and advice from CHM
Signal detection
Signal Evaluation and Prioritisation
Impact Analysis
Regulatory action and communication
43How is the Yellow Card data used to improve
patient safety?
- Changes to SPC e.g. restriction in use, special
warnings and precautions - Publication of
- Issue of Dear Healthcare professional letters
- Drug Analysis Prints (DAPs)
- Withdrawal of a medicines if patient safety is
threatened
44Drug Safety Update
- Published monthly
- Register for alerts
- http//www.mhra.gov.uk/Publications/Safetyguidance
/DrugSafetyUpdate/index.htm
45Drug Analysis Prints (DAPs)
- Complete list of all suspected ADRs reported via
yellow card scheme for named suspect drug - Inclusion of a particular reaction does not
necessarily mean it has been caused by the drug - Certain reported reactions are conditions which
occur spontaneously - Should not be used for determining incidence
- Reporting rates are influenced by seriousness of
ADR, ease of recognition, extent of use -
- www.mhra.gov.uk/daps
46(No Transcript)
47(No Transcript)
48System Organ Class
Totals
49Reactions under High Level Term (HLT)
Reaction Preferred Term (PT)
50Examples of ADRs identified by Yellow Card Scheme
- Vigabatrin and visual field defects
- 3 reports severe persistent visual field
constriction - detected 2-3 years after starting therapy
- resulted in a change of recommended dosage, range
of indications and addition of warnings - Cyproterone acetate and hepatotoxicity
- dose related
- restricted indications
- requirement for hepatic function monitoring
- Alendronate and severe oesophageal reactions
- warnings and revised dosing instructions
- Varenicline and depression and suicidal ideation
- reports received in the 1st 12 months after
launch - addition of warnings and monitoring in patients
with - history of psychiatric illness
51Where to find ADR information
- Reference texts
- British National Formulary (BNF)
- Summary of Product Characteristics (SPC)
- Martindale
- AHFS Drug information
- Meylers 'The Side effects of drugs
- Davies textbook Adverse Drug Reactions
- Lees textbook Adverse Drug Reactions
- Journals
- Adverse Drug Reaction Bulletin
- Drug Safety Update
- Medline/Embase/Pharmline search
- Electronic sources
- Micromedex
- www.mhra.gov.uk
52All health-care professionals have a
responsibility to inform colleagues about
clinically important adverse drug reactions that
they detect, even if a well-recognised or causal
link is uncertain. Edwards IR and Aronson
JK. Adverse drug reactions definitions,
diagnosis, and management. Lancet 2000 356
1255-59
53If you suspect an ADR. do not assume someone
else will report it!
www.mhra.gov.uk/yellowcard